Alnylam Claims Tekmira Infringed RNAi Tech Patents

Law360, New York (January 18, 2012, 9:28 PM EST) -- Alnylam Pharmaceuticals Inc. filed suit Tuesday in Massachusetts federal court against Tekmira Pharmaceuticals Corp., alleging Canada-based Tekmira infringed six patents by selling gene-therapy-related molecules to pharmaceutical giant Bristol-Myers Squibb Co.

The suit claims Tekmira went beyond the scope of a licensing agreement when it agreed to provide small interfering RNA, or RNAi, molecules to Bristol-Myers Squibb in exchange for “an upfront fee of $3 million plus additional consideration,” in deals announced in 2010 and 2011, according to the complaint. Those molecules can be used to effectively...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.